Combination Anti-Diabetes Drugs Market Size
| Study Period | 2019- 2029 |
| Market Size (2024) | USD 1.09 Billion |
| Market Size (2029) | USD 1.85 Billion |
| CAGR (2024 - 2029) | 10.87 % |
| Fastest Growing Market | Europe |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Combination Anti-Diabetes Drugs Market Analysis
The Combination Anti-Diabetes Drugs Market size is estimated at USD 1.09 billion in 2024, and is expected to reach USD 1.85 billion by 2029, growing at a CAGR of 10.87% during the forecast period (2024-2029).
Diabetes mellitus increases the risk of viral infections, especially during the period of poor glycemic control. Emerging evidence suggests that it is one of the most common comorbidities in the SARS-CoV-2 infection. The COVID-19 pandemic has substantially impacted the combination anti-diabetes drugs market. The prevalence of diabetes in people hospitalized with COVID-19 infection and the recognition that improved glycemic control might improve outcomes and reduce the length of stay in patients with SARS-CoV-2 have underlined the importance of the combination anti-diabetes drugs.
People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. Moreover, the management and therapy are complex for individuals with diabetes who are acutely unwell with suspected or confirmed COVID-19. Thus, the COVID-19 outbreak increased the combination anti-diabetes drugs market's growth globally.
Generally, metformin is recommended as an initial treatment for patients with diabetes. At the same time, it is recognized that monotherapy does not provide adequate glucose control in a large proportion of patients and that many patients will experience unacceptable side effects with a higher dosage of a single agent. Fixed dose combination antidiabetic medications are a useful and appropriate treatment option in this large group of patients to maintain good glycemic control. The combination drug therapy helps to keep the HbA1c value below 7% for a patient. Combination therapy at low doses minimizes the side effects associated with high dose therapy of either agent and provides additive clinical benefits.
According to International Diabetes Federation (IDF), the adult diabetes population in 2021 is approximately 537 million, and this number is going to increase by 643 million in 2030. The rate of newly diagnosed cases of Type 1 and Type 2 diabetes is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure worldwide are indications of the increasing usage of anti-diabetic drugs. Technological advancements and innovations have increased over the period leading to several modifications either in the drugs or the formulations being developed.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Combination Anti-Diabetes Drugs Market Trends
Janumet holds the highest market share in the Combination Anti-Diabetes Drugs Market in the current year
Janumet holds the highest market share of about 37.4% in the Combination Anti-Diabetes Drugs Market in the current year.
Janumet contains a combination of metformin and sitagliptin. Metformin and sitagliptin are oral diabetes medicines that help control blood sugar levels. Metformin works by decreasing glucose production in the liver and decreasing glucose absorption by the intestines. Sitagliptin works by regulating the insulin levels the body produces after eating. Janumet is used with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. Janumet is not used to treat type 1 diabetes.
Combination oral drugs are available internationally and are recommended for use when escalation of treatment for type 2 diabetes is required, along with lifestyle management. Oral agents are typically the first medications used in treating type 2 diabetes due to their wide range of efficacy, safety, and mechanisms of action. Combination oral drugs help diabetes patients to keep their condition under control and lower the risk of diabetes complications. People with diabetes may need to take anti-diabetic drugs for their whole lives to control their blood glucose levels and avoid hypoglycemia and hyperglycemia. Oral anti-diabetic agents present the advantages of easier management and lower cost. So they became an attractive alternative to insulin with better acceptance, which enhances adherence to the treatment.
Globally, people witnessed an alarming increase in the prevalence of diabetes in recent years. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as oral anti-diabetic medication or ingestion of additional carbohydrates by monitoring their blood glucose levels. The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic drugs.
Owing to the factors above and the increasing prevalence, the market will likely continue to grow.
North America is expected to dominate the Combination Anti-Diabetes Drugs market over the forecast period
North America is expected to register a CAGR of about 6.5% in the Combination Anti-Diabetes Drugs market over the forecast period.
Combination Anti-diabetic drugs are medicines developed to stabilize and control blood glucose levels among people with diabetes. According to the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research, 'Patients want effective treatment options for diabetes that are as minimally intrusive on their lives as possible, and the FDA welcomes the advancement of new therapeutic options that can make it easier for patients to control their condition.'
Most health insurance plans cover diabetes medications because they are considered medically necessary. Medicare generally covers diabetes medications. The American Diabetes Association includes a guide to Medicare and diabetes prescription drug benefits. For patients covered by insurance, typical out-of-pocket costs consist of a prescription drug copay ranging from USD 10 to USD 50, depending on the drug. If the patient takes multiple drugs, copays can total USD 200 monthly or more.
An estimated 1.4 million Americans are diagnosed with diabetes every year, according to the American Diabetes Association. Diabetes is one of the leading causes of death in Canada and other North American countries. The disease's growing incidence, prevalence, and progressive nature encouraged the development of new drugs to provide additional treatment options for diabetic patients.
Owing to the factors above, the market is expected to grow during the forecast period.
Combination Anti-Diabetes Drugs Industry Overview
The combination anti-diabetes drugs market is moderately consolidated with manufacturers like Novo Nordisk, Merck, Sanofi, Eli Lilly, and others.
Combination Anti-Diabetes Drugs Market Leaders
-
Boehringer Ingelheim
-
Sanofi Aventis
-
Merck & Co., Inc.
-
Eli Lilly and Company
-
Novo Nordisk A/S
*Disclaimer: Major Players sorted in no particular order
Combination Anti-Diabetes Drugs Market News
July 2022: Glenmark Pharmaceuticals Limited announced that it had launched sitagliptin and its fixed-dose combinations for adults with Type 2 diabetes in India. Glenmark introduced 8 different combinations of sitagliptin-based drugs under the brand name SITAZIT and its variants at an affordable price.
July 2022: European Commission released the Commission Implementing Decision granting marketing authorization under Regulation (EC) No 726/2004 of the European Parliament and the Council for "Sitagliptin/Metformin hydrochloride Accord - sitagliptin / metformin hydrochloride."
Combination Anti-Diabetes Drugs Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Oral Combination
- 5.1.1 Janumet (Sitagliptin and Metformin HCl)
-
5.2 Insulin Combination
- 5.2.1 NovoMix (Biphasic Insulin Aspart)
- 5.2.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
- 5.2.3 Xultophy (Insulin Degludec and Liraglutide)
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Rest of North America
- 5.3.2 Europe
- 5.3.2.1 France
- 5.3.2.2 Germany
- 5.3.2.3 Italy
- 5.3.2.4 Spain
- 5.3.2.5 United Kingdom
- 5.3.2.6 Russia
- 5.3.2.7 Rest of Europe
- 5.3.3 Latin America
- 5.3.3.1 Mexico
- 5.3.3.2 Brazil
- 5.3.3.3 Rest of Latin America
- 5.3.4 Asia-Pacific
- 5.3.4.1 Australia
- 5.3.4.2 China
- 5.3.4.3 India
- 5.3.4.4 Indonesia
- 5.3.4.5 Japan
- 5.3.4.6 Malaysia
- 5.3.4.7 Philippines
- 5.3.4.8 South Korea
- 5.3.4.9 Thailand
- 5.3.4.10 Vietnam
- 5.3.4.11 Rest of Asia-Pacific
- 5.3.5 Middle East and Africa
- 5.3.5.1 Saudi Arabia
- 5.3.5.2 Iran
- 5.3.5.3 Egypt
- 5.3.5.4 Oman
- 5.3.5.5 South Africa
- 5.3.5.6 Rest of Middle East and Africa
6. MARKET INDICATORS
- 6.1 Type 1 Diabetes Population
- 6.2 Type 2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 Company Profiles
- 7.1.1 Novo Nordisk A/S
- 7.1.2 Merck
- 7.1.3 Sanofi
- 7.1.4 Eli Lilly
- 7.1.5 Boehringer Ingelheim
- *List Not Exhaustive
-
7.2 Company Share Analysis
- 7.2.1 Novo Nordisk A/S
- 7.2.2 Merck
- 7.2.3 Sanofi
- 7.2.4 Others
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Combination Anti-Diabetes Drugs Industry Segmentation
Combination anti-diabetes drugs combine two or more different types of diabetes medicines. Many people with diabetes need combination therapy to keep blood glucose levels within the target range and avoid diabetes-related complications. The Combination Anti-Diabetes Drugs Market is segmented into type (oral combinations (Janumet (Sitagliptin and Metformin HCl)) and insulin combinations (NovoMix (Biphasic Insulin Aspart), Ryzodeg (Insulin Degludec and Insulin Aspart), and Xultophy (Insulin Degludec and Liraglutide))), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). The report offers the value (in USD) and volume (in units) for the above segments. Further, the report will cover a segment-wise breakdown (value and volume) for all the countries covered under the Table of Contents.
| Oral Combination | Janumet (Sitagliptin and Metformin HCl) | |
| Insulin Combination | NovoMix (Biphasic Insulin Aspart) | |
| Ryzodeg (Insulin Degludec and Insulin Aspart) | ||
| Xultophy (Insulin Degludec and Liraglutide) | ||
| Geography | North America | United States |
| Canada | ||
| Rest of North America | ||
| Geography | Europe | France |
| Germany | ||
| Italy | ||
| Spain | ||
| United Kingdom | ||
| Russia | ||
| Rest of Europe | ||
| Geography | Latin America | Mexico |
| Brazil | ||
| Rest of Latin America | ||
| Geography | Asia-Pacific | Australia |
| China | ||
| India | ||
| Indonesia | ||
| Japan | ||
| Malaysia | ||
| Philippines | ||
| South Korea | ||
| Thailand | ||
| Vietnam | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | Saudi Arabia |
| Iran | ||
| Egypt | ||
| Oman | ||
| South Africa | ||
| Rest of Middle East and Africa |
Combination Anti-Diabetes Drugs Market Research FAQs
How big is the Combination Anti-Diabetes Drugs Market?
The Combination Anti-Diabetes Drugs Market size is expected to reach USD 1.09 billion in 2024 and grow at a CAGR of 10.87% to reach USD 1.85 billion by 2029.
What is the current Combination Anti-Diabetes Drugs Market size?
In 2024, the Combination Anti-Diabetes Drugs Market size is expected to reach USD 1.09 billion.
Who are the key players in Combination Anti-Diabetes Drugs Market?
Boehringer Ingelheim, Sanofi Aventis, Merck & Co., Inc., Eli Lilly and Company and Novo Nordisk A/S are the major companies operating in the Combination Anti-Diabetes Drugs Market.
Which is the fastest growing region in Combination Anti-Diabetes Drugs Market?
Europe is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Combination Anti-Diabetes Drugs Market?
In 2024, the North America accounts for the largest market share in Combination Anti-Diabetes Drugs Market.
What years does this Combination Anti-Diabetes Drugs Market cover, and what was the market size in 2023?
In 2023, the Combination Anti-Diabetes Drugs Market size was estimated at USD 0.97 billion. The report covers the Combination Anti-Diabetes Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Combination Anti-Diabetes Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Diabetes Combination Drugs Industry Report
Statistics for the 2024 Diabetes Combination Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Diabetes Combination Drugs analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
